Moreover, two different studies with human colorectal cancer (CRC) cells showed that after adaptation to sunitinib, CRC cells switched from a VEGFR-dependent to a NRP1/cMet-dependent pathway promoting treatment evasion, and that targeting NRP1 suppressed migration activation [48, 49]. This evidence concerns the gene MET and colorectal carcinoma.